Successful valganciclovir treatment of post-transplant cytomegalovirus infection in the presence of UL97 mutation N597D

Journal of Medical Virology

Volumn 81, Issue 3, 2009, Pages 507-510

  Iwasenko, Jenna M ^a,b   Scott, Gillian M ^a,b   Rawlinson, William D ^a,b   Keogh, Anne ^c   Mitchell, Daniel ^d   Chou, Sunwen ^d  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Antiviral resistance; Heart transplant; Human cytomegalovirus; Protein kinase

Indexed keywords

CORTICOSTEROID DERIVATIVE; CYCLOSPORIN; GANCICLOVIR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PROTEIN KINASE; STEROID; VALGANCICLOVIR; ANTIVIRUS AGENT; DRUG DERIVATIVE; GANCICLOVIR KINASE; PHOSPHOTRANSFERASE;

ADULT; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CARDIAC GRAFT REJECTION; CASE REPORT; CLINICAL FEATURE; CONGESTIVE CARDIOMYOPATHY; CYTOMEGALOVIRUS INFECTION; GENE MUTATION; HEART GRAFT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; PHENOTYPE; VIRUS LOAD; BLOOD; CYTOMEGALOVIRUS; DRUG EFFECT; GENETICS; HEART TRANSPLANTATION; IC 50; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MISSENSE MUTATION; TREATMENT OUTCOME; VIROLOGY;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5;

ANTIVIRAL AGENTS; BLOOD; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HEART TRANSPLANTATION; HUMANS; INHIBITORY CONCENTRATION 50; MICROBIAL SENSITIVITY TESTS; MUTATION, MISSENSE; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); TREATMENT OUTCOME; VIRAL LOAD;

EID: 60049091315     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21397     Document Type: Article

References (17)

1. Boivin G, Goyette N, Gilbert C, Covington E. 2005. Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis. J Med Virol 77:425-429.
2. Chou S. 1999. Antiviral drug resistance in human cytomegalovirus. Transpl Infect Dis 1:105-114.
3. Chou S, Waldemer RH, Senters AE, Michels KS, Kemble GW, Miner RC, Drew WL. 2002. Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. J Infect Dis 185:162-169.
4. Chou S, Van Wechel LC, Lichy HM, Marousek GI. 2005. Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene. Antimicrob Agents Chemother 49:2710-2715.
5. in renal and heart transplant recipients. Transpl Int 15:570-573.
6. Gilbert C, Boivin G. 2005. Human cytomegalovirus resistance to antiviral drugs. Antimicrob Agents Chemother 49:873-883.
7. Iwasenko JM, Scott GM, Ziegler JB, Rawlinson WD. 2007. Emergence of multiple antiviral resistant CMV strains in a highly immuncompromised patient. J Clin Virol 40:152-155.
8. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. 2000. Emergence of ganciclovir-resistant cytomegalovirus diseases among recipients of solid-organ transplants. Lancet 356:645-649.
9. Littler E, Stuart AD, Chee MS. 1992. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature 358:160-162.
10. Lurain NS, Weinberg A, Crumpacker CS, Chou S. 2001. Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing. Antimicrob Agents Chemother 45:2775-2780.
11. Prichard MN, Gao N, Jairath S, Mulamba G, Krosky P, Coen DM, Parker BO, Pari GS. 1999. A recombinant human cytomegalovirus with a large deletion in UL97 has a severe replication deficiency. J Virol 73:5663-5670.
12. Scott GM, Isaacs MA, Zeng F, Kesson AM, Rawlinson WD. 2004. Cytomegalovirus antiviral resistance associated with treatment induced UL97 (protein kinase) and UL54 (DNA polymerase) mutations. J Med Virol 74:85-93.
13. Singh N. 2006. Antiviral drugs for cytomegalovirus in transplant recipients: Advantages of preemptive therapy. Rev Med Virol 16:281-287.
14. Snydman D. 2006. The case for cytomegalovirus prophylaxis in solid organ transplantation. Rev Med Virol 16:289-295.
15. Springer K, Chou S, Li S, Giller R, Quinones R, Shira J, Weinberg A. 2005. How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. J Clin Microbiol 43:208-213.
16. Sullivan V, Talarico CL, Stanat SC, David M, Coen DM, Biron KK. 1992. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells [erratum for Nature 1992 Jul 9;358:162-4; PMID: 1319560]. Nature 359:85.
17. Wolf DG, Yaniv I, Honigman A, Kassis I, Schonfeld T, Ashkenazi S. 1998. Early emergence of ganciclovir-resistant human cytomegalovirus strains in children with primary combined immunodeficiency. J Infect Dis 178:535-538.